Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intec Pharma

- PMLiVE

AZ, Merck win FDA approval for Lynparza in pancreatic cancer

New treatment option for subset of patients with BRCA-mutations

- PMLiVE

FDA follows EMA with approval of Merck’s Ebola vaccine

First to be approved in the US

- PMLiVE

FDA panel clears Keytruda for hard-to-treat bladder cancer

New treatment option for high-risk patients

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

Novartis ditches oral asthma drug after disappointing phase 3 readout

Bad news for Gossamer’s would-be rival DP2 antagonist

- PMLiVE

Intec battered as Novartis ducks out of Accordion collaboration

Shares fell by more than 12% after the annoucement

- PMLiVE

Merck buys ArQule for $2.7bn in another cancer bolt-on deal

Deal due to close in the first quarter of 2020

- PMLiVE

Novartis strengthens case for its combination asthma drug

Demonstrated significant benefits in uncontrolled asthma patients

- PMLiVE

Novartis highlights emerging assets and late-stage pipeline at R&D day

Also plans to expand established brands into new indications

- PMLiVE

Merck’s Keytruda picks up third approval for NSCLC in China

New indication as a first-line treatment in combination with chemotherapy

- PMLiVE

Novartis acquires The Medicines Company for $9.7bn following takeover rumours

MedCo's cholesterol lowering inclisiran main attraction in planned acquisition

- PMLiVE

MSD’s Keytruda scores another EU okay, in head and neck cancer

First anti-PD-1 drug to improve overall survival in first-line setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links